CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Significant differences exist in the expression of LAAs relevant to CML disease progression and response, and CD34+ progenitor maturation in CML (81, 96), suggesting the importance of combining several antigens in future immunotherapeutic strategies.